Selectin Blocker Market Overview
Selectin blocker drugs are responsible for activation of the cell-mediated immune system and blocking inflammatory reactions. Continuous circulation of leukocytes triggers the immune system of the body. Therefore, selectin bind by cellular adhesions with leukocytes and travel towards the immune cell of inflamed tissue. Uncontrolled adhesion of selectin often contributes to inflammation and progression of cancer.
Inflammatory reaction cell or tumour cells just like leukocytes bind with selectin and expand leading to organ metastasis. Therefore, selectin blocker interfering its adhesion function is necessary to prevent inflammatory reactions or cancer to spread.
According to World Health Organisation, chronic obstructive pulmonary disease accounts a prevalence of 251 million cases globally in 2016.Covid-19 has led to the shift of focus of key players in biopharmaceuticals towards finding a coronavirus cure.
This impacted delay in clinical trials of drugs under the selectin blocker market increasing operating revenue cost. Manufacturing activities and supply chain has been put on halt due to lockdown in several countries impacting selectin blocker market. Pandemic has led to the reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities.
Selectin Blocker Market: Drivers and Restraints
The significant number of candidates under clinical trial is expected to drive selectin blocker market growth during the forecast period. For instance, a drug named Bimosiamose by Encysive Pharmaceuticals and Revotar Biopharmaceuticals is a currently leading candidate of selectin blocker market.
Demand for the drug with better efficacy and fewer side-effects will propel the demand for selectin blocker market during the forecast period. The rise in the prevalence of inflammatory reactions increases the demand for selectin blocker market.
Increasing geriatric population boosts selectin blocker market growth. Stringent regulatory policies for drug approval challenge selectin blocker market growth. Discovery of generic and biosimilar tend to hinder the growth of selectin blocker market.
Selectin Blocker Market: Overview
Non-steroidal anti-inflammatory drugs hold a major revenue share of selectin blocker market because of better efficacy. Based on prescription, clinician prescribed drugs dominate the selectin blocker market as compared to over the counter drugs.
Oral route of administration holds more revenue share in selectin blocker market whereas, intravenous route of administration is expected to observe steady growth during the forecast period. Among indication type, chronic obstructive pulmonary diseases generate highest revenue share in selectin blocker market followed by cancer.
Hospital pharmacies is the largest distribution channel followed by retail pharmacies in the selectin blocker market. Online pharmacies are expected to have significant growth during the forecast period with an increased rate of adoption among the general population.
Selectin Blocker Market: Region-wise Outlook
North America will continue to dominate the selectin blocker market during the forecast period with high rate of approvals and commercialization in the region. Increase in investment towards research and development activities will propel selectin blocker market to grow in the North America region.
Europe is expected to have significant growth in the coming decade with increased awareness and treatment-seeking rates in the selectin blocker market. Asia-Pacific is lucrative for market growth with a rise in the number of domestic players in the region in the coming decade.
Asia-pacific region has a high prevalence rate of COPD which leads to rise in patient population creating demand for selectin blocker market growth. Middle East and Africa are untapped region with very less healthcare spending in selectin blocker market.
Selectin Blocker Market: Key Market Participants
Major players in selectin blocker market include
- Pfizer Inc.
- AbbVie Inc.
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche AG
- Merck and Co. Inc.
- Amgen Inc.
- AstraZeneca PLC.
- Eli Lily and Company
- Johnson and Johnson Inc.
- Novartis AG
- Sanofi S.A.
- Selexys Pharmaceuticals
- GlycoMimetics Inc.
- Cantex Pharmaceuticals
- ParinGenix Inc.
- ProtoKinetix Inc.
- Encysive pharmaceuticals Inc.
- Revotar Biopharmaceuticals AG
- Cytel Inc.
The research report on selectin blocker market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on selectin blocker market provides analysis and information according to market segments such as drug class, route of administration, application, and region.
The report covers exhaust analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, Italy, France, U.K, Spain, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Selectin Blocker Market Segmentation
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Over the counter
- Over the counter
- Hospital pharmacies
- Retail pharmacies
- Drug stores
- Online pharmacies